207 related articles for article (PubMed ID: 11920637)
1. alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin.
Taga T; Suzuki A; Gonzalez-Gomez I; Gilles FH; Stins M; Shimada H; Barsky L; Weinberg KI; Laug WE
Int J Cancer; 2002 Apr; 98(5):690-7. PubMed ID: 11920637
[TBL] [Abstract][Full Text] [Related]
2. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist.
MacDonald TJ; Taga T; Shimada H; Tabrizi P; Zlokovic BV; Cheresh DA; Laug WE
Neurosurgery; 2001 Jan; 48(1):151-7. PubMed ID: 11152340
[TBL] [Abstract][Full Text] [Related]
3. Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist.
Belvisi L; Riccioni T; Marcellini M; Vesci L; Chiarucci I; Efrati D; Potenza D; Scolastico C; Manzoni L; Lombardo K; Stasi MA; Orlandi A; Ciucci A; Nico B; Ribatti D; Giannini G; Presta M; Carminati P; Pisano C
Mol Cancer Ther; 2005 Nov; 4(11):1670-80. PubMed ID: 16275988
[TBL] [Abstract][Full Text] [Related]
4. The human integrin alpha 8 beta 1 functions as a receptor for tenascin, fibronectin, and vitronectin.
Schnapp LM; Hatch N; Ramos DM; Klimanskaya IV; Sheppard D; Pytela R
J Biol Chem; 1995 Sep; 270(39):23196-202. PubMed ID: 7559467
[TBL] [Abstract][Full Text] [Related]
5. A selective cyclic integrin antagonist blocks the integrin receptors alphavbeta3 and alphavbeta5 and inhibits retinal pigment epithelium cell attachment, migration and invasion.
Hoffmann S; He S; Jin M; Ehren M; Wiedemann P; Ryan SJ; Hinton DR
BMC Ophthalmol; 2005 Jun; 5():16. PubMed ID: 15987521
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
[TBL] [Abstract][Full Text] [Related]
7. A small-molecule RGD-integrin antagonist inhibits cell adhesion, cell migration and induces anoikis in glioblastoma cells.
Russo MA; Paolillo M; Sanchez-Hernandez Y; Curti D; Ciusani E; Serra M; Colombo L; Schinelli S
Int J Oncol; 2013 Jan; 42(1):83-92. PubMed ID: 23174862
[TBL] [Abstract][Full Text] [Related]
8. EGFRvIII/integrin β3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis.
Liu Z; Han L; Dong Y; Tan Y; Li Y; Zhao M; Xie H; Ju H; Wang H; Zhao Y; Zheng Q; Wang Q; Su J; Fang C; Fu S; Jiang T; Liu J; Li X; Kang C; Ren H
Oncotarget; 2016 Jan; 7(4):4680-94. PubMed ID: 26717039
[TBL] [Abstract][Full Text] [Related]
9. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins.
Mitjans F; Meyer T; Fittschen C; Goodman S; Jonczyk A; Marshall JF; Reyes G; Piulats J
Int J Cancer; 2000 Sep; 87(5):716-23. PubMed ID: 10925366
[TBL] [Abstract][Full Text] [Related]
10. The aryl hydrocarbon receptor links integrin signaling to the TGF-β pathway.
Silginer M; Burghardt I; Gramatzki D; Bunse L; Leske H; Rushing EJ; Hao N; Platten M; Weller M; Roth P
Oncogene; 2016 Jun; 35(25):3260-71. PubMed ID: 26500056
[TBL] [Abstract][Full Text] [Related]
11. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
[TBL] [Abstract][Full Text] [Related]
12. Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells.
Maubant S; Saint-Dizier D; Boutillon M; Perron-Sierra F; Casara PJ; Hickman JA; Tucker GC; Van Obberghen-Schilling E
Blood; 2006 Nov; 108(9):3035-44. PubMed ID: 16835373
[TBL] [Abstract][Full Text] [Related]
13. Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the alpha v beta 3 integrin to promote epidermal growth factor receptor phosphorylation and growth.
Jones PL; Crack J; Rabinovitch M
J Cell Biol; 1997 Oct; 139(1):279-93. PubMed ID: 9314546
[TBL] [Abstract][Full Text] [Related]
14. Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.
Xia S; Lal B; Tung B; Wang S; Goodwin CR; Laterra J
Neuro Oncol; 2016 Apr; 18(4):507-17. PubMed ID: 26320116
[TBL] [Abstract][Full Text] [Related]
15. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide.
Erdreich-Epstein A; Shimada H; Groshen S; Liu M; Metelitsa LS; Kim KS; Stins MF; Seeger RC; Durden DL
Cancer Res; 2000 Feb; 60(3):712-21. PubMed ID: 10676658
[TBL] [Abstract][Full Text] [Related]
16. Antisense to integrin alpha v inhibits growth and induces apoptosis in medulloblastoma cells.
MacDonald TJ; Ladisch S
Anticancer Res; 2001; 21(6A):3785-91. PubMed ID: 11911248
[TBL] [Abstract][Full Text] [Related]
17. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
Burke PA; DeNardo SJ; Miers LA; Lamborn KR; Matzku S; DeNardo GL
Cancer Res; 2002 Aug; 62(15):4263-72. PubMed ID: 12154028
[TBL] [Abstract][Full Text] [Related]
18. IS20I, a specific alphavbeta3 integrin inhibitor, reduces glioma growth in vivo.
Bello L; Lucini V; Giussani C; Carrabba G; Pluderi M; Scaglione F; Tomei G; Villani R; Black PM; Bikfalvi A; Carroll RS
Neurosurgery; 2003 Jan; 52(1):177-85; discussion 185-6. PubMed ID: 12493116
[TBL] [Abstract][Full Text] [Related]
19. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.
Li L; Wartchow CA; Danthi SN; Shen Z; Dechene N; Pease J; Choi HS; Doede T; Chu P; Ning S; Lee DY; Bednarski MD; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1215-27. PubMed ID: 15001266
[TBL] [Abstract][Full Text] [Related]
20. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy.
Carron CP; Meyer DM; Pegg JA; Engleman VW; Nickols MA; Settle SL; Westlin WF; Ruminski PG; Nickols GA
Cancer Res; 1998 May; 58(9):1930-5. PubMed ID: 9581835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
